Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Automatically detect candlestick patterns on any chart

Read How
Market News Market Pulse Stocks News ETF News Crypto News

Atea Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Atea Pharmaceuticals, Inc.

Aug-12
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update AVIR GlobeNewswire
Aug-05
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026 AVIR GlobeNewswire
Jul-28
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus AVIR -6.43% GlobeNewswire
Jul-14
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus AVIR GlobeNewswire
Jun-25
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus AVIR GlobeNewswire
May-27
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026 AVIR GlobeNewswire
May-13
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline AVIR -16.91% GlobeNewswire
May-12
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update AVIR GlobeNewswire
May-05
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026 AVIR GlobeNewswire
Mar-05
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update AVIR +6.43% AVIR +11.13% GlobeNewswire
Feb-26
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026 AVIR GlobeNewswire
Feb-24
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026 AVIR GlobeNewswire
Jan-08
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference AVIR GlobeNewswire
Jan-06
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference AVIR GlobeNewswire
Dec-22
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus AVIR GlobeNewswire
Nov-19
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference AVIR GlobeNewswire
Nov-12
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update AVIR AVIR -12.57% GlobeNewswire
Nov-07
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting 2025 AVIR GlobeNewswire
Nov-05
Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025 AVIR GlobeNewswire
Oct-22
Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025 AVIR GlobeNewswire
Oct-07
Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting 2025 AVIR GlobeNewswire
Sep-02
Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference AVIR GlobeNewswire
Aug-07
Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update AVIR GlobeNewswire
Jul-31
Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025 AVIR GlobeNewswire
Jun-24
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America AVIR GlobeNewswire
May-12
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update AVIR +8.82% AVIR -11.15% GlobeNewswire
May-07
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025 AVIR GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)